细胞因子诱导的杀伤细胞/树突状细胞联合细胞因子诱导的杀伤细胞免疫治疗晚期胃肠道癌。

Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer.

机构信息

Department of Gastrointestinal Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Biochemistry & Molecular Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出版信息

BMC Cancer. 2020 Apr 28;20(1):357. doi: 10.1186/s12885-020-06860-y.

BACKGROUND

This study aimed to investigate the efficacy and safety of cytokine-induced killer (CIK)/dendritic cell combined with CIK (DC-CIK) cell therapy in advanced gastrointestinal cancer (GIC).

METHODS

The PubMed, Cochrane library, and Embase were searched to conduct a meta-analysis of clinical controlled trials to evaluate the efficacy and safety of CIK/DC-CIK cell therapy in advanced GIC. The pooled risk ratios (RRs) or weighted mean difference (WMD) with 95% confidence intervals (95% CIs) were calculated.

RESULTS

A total of nine studies with 1113 patients were identified. The overall survival (RR = 1.84, 95% CI = 1.41-2.40, P = 0.654, I = 0%), progression-free survival (RR = 1.99, 95% CI = 1.52-2.60, P = 0.727, I = 0%), and quality of life (WMD = 16.09, 95% CI = 1.66-30.52, P < 0.001, I = 98.8%) were significantly improved in patients who received chemotherapy combined with CIK/DC-CIK cells, and no severe adverse events were reported.

CONCLUSION

This meta-analysis suggested that the combination of CIK/DC-CIK immunotherapy and chemotherapy was safe and applicable for patients with advanced GIC. It is a feasible choice to prolong survival and improve quality of life.

背景

本研究旨在探讨细胞因子诱导的杀伤（CIK）/树突状细胞联合 CIK（DC-CIK）细胞治疗在晚期胃肠道癌（GIC）中的疗效和安全性。

方法

检索 PubMed、Cochrane 图书馆和 Embase，对临床对照试验进行荟萃分析，评估 CIK/DC-CIK 细胞治疗在晚期 GIC 中的疗效和安全性。计算合并的风险比（RR）或加权均数差（WMD）及其 95%置信区间（95%CI）。

结果

共纳入 9 项研究，共计 1113 例患者。化疗联合 CIK/DC-CIK 细胞治疗的患者总生存期（RR=1.84，95%CI=1.41-2.40，P=0.654，I²=0%）、无进展生存期（RR=1.99，95%CI=1.52-2.60，P=0.727，I²=0%）和生活质量（WMD=16.09，95%CI=1.66-30.52，P<0.001，I²=98.8%）显著改善，且未报告严重不良事件。